Effective induction of immune responses to whole, subunit, or synthetic peptide vaccines often requires coadministration of adjuvants or immunomodulators. Recent research has led to the identification of a number of clinically acceptable adjuvants which are more potent and efficacious than the alum-type adjuvants (16, 17) . Many of these compounds are comparable to the "gold standard," i.e., complete Freund's adjuvant (CFA), in inducing strong and/or protective immunities against many infectious diseases in animal models (16, 17) .
While the discoveries of potentially effective adjuvants for human vaccines are encouraging, little is known regarding the mechanisms of action of vaccine adjuvants in inducing a particular immune response during in vivo, active immunizations. This is of particular concern since vaccine adjuvants can have profound effects on the qualities of immune responses induced. As examples, studies on animals immunized with malaria vaccine antigens (i.e., sporozoite, merozoite, and gametocyte antigens) show that adjuvants influence the specificities of immune responses induced, the major histocompatibility complex-regulated responsiveness to epitopes, and the induction of protective immunity (4, 11, 13, 17, 18, 20, 28, 35, 41) . Furthermore, the responses to adjuvants often vary with animal species or subspecies (17) . Such differential influences on immune responses occur despite the pleomorphic effects of adjuvants on a variety of immune cells, and such effects often overlap among different classes of adjuvants (16, 17, 22, 38, 39) .
We hypothesize that during active immunizations, vaccine adjuvants selectively or preferentially utilize different immune pathways for the potentiation of an immune response. These may be in the form of cytokine-potentiated pathways, selective costimulatory interactions, and/or preferential activation of subpopulations of immune cells. To begin to address this issue, we investigated the requirement of gamma interferon (IFN-␥)-and interleukin-4 (IL-4)-mediated immune pathways for the potentiation of immunogenicity to a well-known Plasmodium falciparum blood-stage malaria vaccine antigen, the major merozoite surface protein 1 (MSP1) (8) . Mice with homozygotic disruption of the IFN-␥ or IL-4 gene were immunized with a recombinant MSP1 antigen (24) (18) (19) (20) adjuvant formulations. Past studies have shown that protective immunity against MSP1 is primarily antibody mediated (5, 8, 10) , and thus we examined the induction of anti-MSP1 antibodies by adjuvants. Our results revealed a spectrum of requirements for cytokine-mediated pathways for immunopotentiation, and such requirements were subjected to dynamic influences among components of the adjuvant formulations. Furthermore, utilization of immune pathways by an adjuvant differed among mouse strains and subspecies. on October 14, 2017 by guest http://iai.asm.org/ atively independent of IL-4. By contrast, IL-4 knockout caused significant IgG2a or IgG2b production in the mice receiving B30-MDP/liposomes and alum, while these isotypes were undetectable or minimally produced in IL-4 ϩ/ϩ mice (P Ͻ 0.001) (Fig. 4 and 6) .
RESULTS

Immunogenicity
Immunogenicity of P2P30-MSP1-19 in C57BL/6 IL-4
؊/؊ and C57BL/6 IL-4 ؉/؉ mice. Anti-MSP1-19 antibody responses were unaffected by IL-4 knockout in CFA immunizations (Fig.  7) . However, the antibody levels were significantly lower in IL-4 Ϫ/Ϫ mice receiving LA-15-PH/liposomes than in controls (P Ͻ 0.05) (Fig. 7) .
Isotypes of anti-MSP1-19 antibodies in C57BL/6 IL-4
؊/؊ and C57BL/6 IL-4 ؉/؉ mice. A prominent effect of IL-4 knockout was the near-complete abrogation of IgG1 antibodies after CFA immunization (Fig. 8) . For LA-15-PH/liposomes, IgG1 was only minimally detected in IL-4 ϩ/ϩ mice and undetectable in IL-4 Ϫ/Ϫ mice (Fig. 8 ). There were also increases in IgG2b production in IL-4 Ϫ/Ϫ mice for both adjuvants. Thus, the IL-4-dependent pathway of anti-MSP1-19 IgG1 production was utilized in C57BL/6 mice immunized with CFA but not LA-15-PH/liposomes. On the other hand, the absence of IgG2a antibodies suggests that both adjuvants did not utilize Th1-mediated pathways for the production of anti-MSP1-19 antibodies.
Basis for animal species differences in responses to adjuvants. Animal species differences in responses to an adjuvant may result from disparate usages of cytokine-mediated immune pathways by an adjuvant. This is seen in the IL-4-regulated IgG1 responses induced by CFA and LA-15-PH/liposomes in BALB/c and C57BL/6 mice ( Table 1 ). In the BALB/c background, CFA and LA-15-PH/liposomes induced IgG1 responses, and these antibodies were dominant in IFN-␥ Ϫ/Ϫ mice. The IgG1 responses induced by both adjuvants were regulated by IL-4, as seen in BALB/c IL-4 Ϫ/Ϫ mice. In the C57BL/6 background, only CFA, not LA-15-PH/liposomes, was able to induce IL-4-dependent IgG1 responses. The inability of C57BL/6 mice to produce appreciable levels of anti-MSP1-19 IgG1 in response to LA-15-PH/liposomes was not due to an inherent defect of this mouse strain since CFA readily induced these antibodies in C57BL/6 mice.
DISCUSSION
The results of this study suggest that adjuvants utilize different cytokine-mediated immune pathways to potentiate the immunogenicity of an antigen and/or to uniquely affect the quality or specificity of immune responses. Our results further suggest that the in vitro or in vivo immunoactivities of adjuvants do not always predict or correspond to the adjuvants' requirements of immune mediators for immunopotentiation. For example, both LA-15-PH and B30-MDP induce IFN-␥, -␣, and -␤ (22, 38, 39), but they do not depend on IFN-␥ for the immunopotentiation of MSP1-19.
Comparisons of the Th1-and Th2-type antibodies offered clues to the mode of action of these adjuvants. The induction of Th2-type (IgG1) antibodies exclusively by B30-MDP/liposomes or predominantly by alum would explain why a defi- (39) and enhance the antigen-processing capabilities of macrophages (43) . It is possible that compensatory immune mechanisms were utilized by some adjuvants in IFN-␥ Ϫ/Ϫ mice for antibody production. Recent studies suggest that IL-12 plays a major role in the development of antibody responses (27) . In these studies, IL-12 exerts its influence via up-regulation of IFN-␥ production, resulting in enhanced IgG2a production. pathways in IL-4 Ϫ/Ϫ mice was not fully compensated for by IL-4-independent mechanisms induced by CFA or alum.
IL-4 may affect an adjuvant's ability to induce Th1-like, IgG2a responses. In IL-4 Ϫ/Ϫ mice immunized with OVA in alum, a vigorous IgG2a response was produced, whereas no detectable IgG2a was observed in IL-4 ϩ/ϩ mice (3). Our results for IL-4 Ϫ/Ϫ mice immunized with P2P30-MSP1-19 in alum were in agreement with these studies. Moreover, our findings that immunization with B30-MDP/liposomes was also able to induce IgG2a in IL-4 Ϫ/Ϫ but not IL-4 ϩ/ϩ mice clearly demonstrate that this is not a phenomenon peculiar to alum. Thus, the immunopotentiating activities of adjuvants such as alum and B30-MDP/liposomes may be regulated by the cytokine (e.g., IL-4) milieu of the host.
Our findings regarding the IL-4-regulated IgG1 responses induced by CFA and LA-15-PH/liposomes in BALB/c and C57BL/6 mice suggest that animal species differences in response to an adjuvant may result from disparate usages of cytokine-mediated immune pathways by the adjuvant. We hypothesize that specific immune cells in one mouse strain which mediate a particular pathway may be more sensitive or permissive to stimulation by an adjuvant formulation than the analogous cell populations from another strain. On the other hand, the types of immune cells stimulated by an adjuvant may be different among mouse strains. Alternatively, nonimmune factors unique to the genetic background of one mouse strain may influence the activities of adjuvants.
This investigation focused on the antigen P2P30-MSP1-19. A logical question is whether the immune pathways utilized by an adjuvant vary with the particular immunogen. Studies have shown that for antigens that are weak or neutral in their abilities to polarize immune responses (e.g., Th1 versus Th2), adjuvants play a critical role in determining the profiles of immune responses (7) . In these scenarios, the immune pathways utilized by an adjuvant may be identical or similar irrespective of the antigen used. On the other hand, some antigens possess intrinsic adjuvanticities, and administration of these antigens alone can polarize the profile of immune responses. The Leishmania protein LelF and the Schistosoma mansoni soluble egg antigens are examples which polarize for Th1 and Th2 responses, respectively (25, 31, 33, 36) . Immunization with these antigens may enhance or limit the effectiveness of adjuvants, depending on whether the profiles of immune responses associated with the immunogen and with the adjuvant are opposing or complementary. Polarization of immune responses by an antigen may limit the availability of an immune pathway that is principally utilized by an adjuvant, which may then default to other pathways for immunopotentiation. These hypotheses are readily testable in appropriate gene knockout models. Finally, it is known that the affinity of an antigen for the T-cell receptor, the strength of T-cell receptor signalling, and the density of major histocompatibility complex class II ligands may influence immune response profiles (15, 40) . Whether these factors affect the immune mediator usage by adjuvants remains to be determined.
